The efficacy of systemic therapy varies among patients with rare skin cancers, but patients with cutaneous adnexal carcinoma have poor outcomes regardless of the therapy they receive, according to ...
Median disease-free survival (DFS) increased from 4.8 months with placebo to 9.9 months with adjuvant atezolizumab (Tecentriq ...
In real-world clinical practice, managing atopic dermatitis presents many challenges, particularly when ideal treatments are ...
Colorectal cancer (CRC) is one of the most common malignant cancers and its incidence is steadily rising particularly in ...
Verzenio plus endocrine therapy reduced death risk by 15.8% in high-risk early breast cancer patients compared to endocrine ...
Please provide your email address to receive an email when new articles are posted on . One specialist highlighted cases in which systemic treatments, such as corticosteroids, are better. Another ...
Patients with noninfectious intermediate, posterior, or panuveitis requiring immunosuppressive therapy are less likely to ...
Trial met primary endpoint achieving statistically significant improvement in disease activity, with 67.1% of patients responding with ...
Detailed results from bezuclastinib’s positive SUMMIT trial evaluating bezuclastinib in patients with NonAdvanced Systemic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback